[114] randomized subjects to semaglutide or placebo to observe the change of liver fat from baseline to week 48, and found that semaglutide significantly reduced hepatic steatosis, improved liver enzymes and metabolic parameters, and had a positive effect on the diagnosis and treatment of NAFLD compared with placebo
Nobody really wants to start a patient on a drug that isn't clinically indicated
2006;118(3 Suppl)L108S120S
(Unless the client experiences sudden blindness in one eye or its a NAION lawsuit) ++++ Eli Lillys tirzepatide products (Zepbound and Mounjaro) unite GLP-1 medication with a hormone that is hunger-related, named GIP
GLP-1 receptor agonists are licensed in the UK for type 2 diabetes mellitus and specific weight management indications, not for cognitive impairment or dementia GLP-1 receptors are present in brain regions involved in memory and learning, prompting research into potential neuroprotective effects Ongoing clinical trials, including studies of semaglutide in Alzheimer's disease, are examining whether these medications benefit cognitive function Common adverse effects include gastrointestinal symptoms